NVCR PDUFA Date: TTFields therapy Page updated September 23, 2026 · next FDA decision on the calendar · Data as of Oct 11, 2026 9:31 PM ET FDA decision (PDUFA) target Q4 2026 · NovoCure Limited · Brain metastases from non-small cell lung cancer (PMA, Breakthrough Device)
Key facts FDA PDUFA target date Q4 2026
Drug / candidate TTFields therapy (Optune)
Indication Brain metastases from non-small cell lung cancer (PMA, Breakthrough Device)
Company NovoCure Limited
New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs .
See the full 2026 PDUFA calendar → All Q4 2026 PDUFA dates → FAQ When is the NVCR PDUFA date? The FDA PDUFA target date for NVCR (NovoCure Limited) is Q4 2026 for TTFields therapy (Optune). The sponsor has guided this window, not a specific day; the date shown is the window, at the precision the source gave. Dates are company/FDA-sourced and can slip. Verify against primary filings.
What is NVCR's drug TTFields therapy? TTFields therapy (Optune) is NovoCure Limited's candidate under FDA review for Brain metastases from non-small cell lung cancer (PMA, Breakthrough Device).
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.